14 stories mentioning URGNUpdated 20d ago
Every FINWIRES story that references URGN, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Mark Schoenberg, Chief Medical Officer, on August 20, 2026, sold 60,677 shares in Urogen Pharma (URGN) for $2,854,853. Following the Form 4 filing with the SEC, Schoenberg has control over a total of 59,086 ordinary shares of the company, with 59,086 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668243/000143774926028840/xslF345X05/rdgdoc.xml
Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) climbed up 1.8%.In corporate news, UroGen Pharma (URGN) shares rose 2.1% after the firm said it has submitted a new drug application to the US Food and Drug Administration for UGN-103 to treat adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.Argenx (ARGX) shares surged past 16% after the company said a phase 3 study evaluating its experimental drug Vyvgart Hytrulo in adults with autoimmune myositis met its main goal.Mesoblast (MESO) shares jumped nearly 10% after the company said it has completed patient treatment in a phase 3 trial of its experimental rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.EyePoint (EYPT) shares tumbled 68% after it said its phase 3 Lugano trial testing Duravyu in people with wet age-related macular degeneration failed to achieve its primary endpoint.
Healthcare stocks were slightly higher Monday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.1%.The iShares Biotechnology ETF (IBB) climbed up 1.8%.In corporate news, UroGen Pharma (URGN) shares rose 2.5% after the firm said it has submitted a new drug application to the US Food and Drug Administration for UGN-103 to treat adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
UroGen Pharma (URGN) has an average rating of buy and mean price target of $56.25, according to analysts polled by FactSet.Price: $46.43, Change: $+6.51, Percent Change: +16.31%
UroGen Pharma (URGN) has an average rating of buy and mean price target of $41.62, according to analysts polled by FactSet.Price: $46.16, Change: $+6.24, Percent Change: +15.62%
UroGen Pharma (URGN) has an average rating of buy and mean price target of $41.62, according to analysts polled by FactSet.Price: $40.31, Change: $+0.51, Percent Change: +1.28%
Mark Schoenberg, Chief Medical Officer, on July 09, 2026, sold 10,000 shares in Urogen Pharma (URGN) for $400,000. Following the Form 4 filing with the SEC, Schoenberg has control over a total of 119,763 ordinary shares of the company, with 119,763 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668243/000143774926023290/xslF345X05/rdgdoc.xmlPrice: $39.70, Change: $-0.53, Percent Change: -1.32%
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding about 1.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In sector news, Boston Scientific (BSX) shares gained 1.9% after the company said Tuesday a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the company said. Its shares rose 3%.UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with a physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said in a note. UroGen shares were down 0.8%.MetaVia (MTVA) shares surged 64% Tuesday, a day after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In sector news, UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with the physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said in a note. UroGen shares were down 0.5%.
UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with the physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said Tuesday.The physician panel said Zusduri has a competitive advantage since it is first to market, requires no biomarker testing, can be used without transurethral resection of bladder tumor or TURBT surgery, and has a finite six-dose treatment course, according to the note.One panelist argued that Zusduri offers better long-term durability than surgery, with roughly a 65% chance of no tumor recurrence at three years, something TURBT cannot offer, the brokerage said.The treatment seems operationally feasible and reimbursement concerns are easing, but Medicare Advantage plans remain a risk because clinics could still lose money despite the drug being officially covered, the brokerage added.Oppenheimer's above-consensus Zusduri revenue estimates for 2026 to 2030 of $204 million, $411 million, $595 million, $771 million, and $931 million remain unchanged.The brokerage kept an outperform rating on UroGen Pharma with a price target of $40.Price: $27.64, Change: $-0.94, Percent Change: -3.29%
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% and the State Street Healthcare Select Sector SPDR ETF (XLV) increasing 0.5%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, Personalis (PSNL) shares jumped past 7% after the company said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services expanded coverage for its NeXT Personal minimal residual disease test.Assertio (ASRT) shares rose 3.4% after the company said Wednesday it agreed to be acquired by Zydus Lifesciences subsidiary Zydus Worldwide DMCC in an all-cash tender offer valued at about $166.4 million.UroGen Pharma's (URGN) Zusduri treatment demonstrated a 64.5% 36-month duration of response in a pivotal phase 3 trial in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, the company said Wednesday. Its shares rose 1.9%.
Mark Schoenberg, Chief Medical Officer, on May 08, 2026, sold 10,000 shares in Urogen Pharma (URGN) for $300,000. Following the Form 4 filing with the SEC, Schoenberg has control over a total of 134,985 ordinary shares of the company, with 134,985 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668243/000143774926016104/xslF345X05/rdgdoc.xmlPrice: $31.50, Change: $+2.10, Percent Change: +7.14%
UroGen Pharma (URGN) has an average rating of buy and mean price target of $34.62, according to analysts polled by FactSet.Price: $25.55, Change: $-0.70, Percent Change: -2.69%
UroGen Pharma (URGN) shares were up 9.9% in early trading on Wednesday after the company posted a narrower net loss and higher revenue for Q1.The company reported a Q1 net loss of $0.47 per diluted share, narrower than a loss of $0.92 a year earlier.Analysts polled by FactSet expected a loss of $0.48.Revenue for the quarter ended March 31 was $51 million, up from $20.3 million a year earlier.Analysts expected revenue of $44.8 million.As of March 31, the company said it had $140.3 million in cash, cash equivalents and marketable securities on hand.Price: $26.25, Change: $+2.42, Percent Change: +10.16%
